Abstract
Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.
Highlights
This article, published in the March 2012 issue of EMBO Molecular Medicine, contained text passages similar to those from a number of previous publications, many by the same authors: “Cancer microRNAs: from subtype profiling to predictors of response to therapy” by Chan E, Pardo DE, Weidhaas JB in Trends Mol Med 17: 235–243; “Targeting microRNAs in cancer: rationale, strategies and challenges” by Garson R, Marcucci G, Croce CM in Nat Rev Drug Discov 9: 775–789; “MicroRNAs in cancer: small molecules with a huge impact” by Iorio MV, Croce CM in J Clin Oncol 27: 5848–5856; and “Breast cancer and microRNAs: therapeutic impact” by Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E in Breast 20 Suppl. 3: S63–S70
A number of later publications overlap with text from this reference without formal citations
Rijeka: InTech; “microRNA involvement in human cancer” by Iorio MV, Croce CM in Carcinogenesis 33: 1126–1133; and “Causes and consequences of microRNA dysregulation” by Iorio MV, Croce CM in Cancer J, 18: 215–222
Summary
This article, published in the March 2012 issue of EMBO Molecular Medicine, contained text passages similar to those from a number of previous publications, many by the same authors: “Cancer microRNAs: from subtype profiling to predictors of response to therapy” by Chan E, Pardo DE, Weidhaas JB in Trends Mol Med 17: 235–243; “Targeting microRNAs in cancer: rationale, strategies and challenges” by Garson R, Marcucci G, Croce CM in Nat Rev Drug Discov 9: 775–789; “MicroRNAs in cancer: small molecules with a huge impact” by Iorio MV, Croce CM in J Clin Oncol 27: 5848–5856; and “Breast cancer and microRNAs: therapeutic impact” by Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E in Breast 20 Suppl. 3: S63–S70.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
